摘要
目的初探利巴韦林联合聚乙二醇干扰素α-2a治疗慢性丙肝的效果。方法选取我院收治慢性丙肝患者48例,随机分为对照组和治疗组(各24例),对照组在常规治疗基础上采用利巴韦林进行治疗,治疗组在对照组治疗基础上联合聚乙二醇干扰素α-2a进行治疗,比较两组临床疗效。结果治疗组ETVR、EVR、NR、SVR等HCVRNA转阴情况均优于对照组,差异有统计学意义(P<0.05);治疗组患者治疗后AST、ALT等肝功能指标改善效果与对照组之间对比,差异有统计学意义(P<0.05);两组患者的不良反应发生率比较,对照组高于治疗组,组间差异有统计学意义(P<0.05)。结论利巴韦林联合聚乙二醇干扰素α-2a治疗慢性丙肝效果显著,安全可靠。
Objective To study the effect of ribavirin combined with pegylated interferon α-2a on chronic hepatitis C. Methods 48 cases with chronic hepatitis C were selected and randomly divided into the control group and the treatment group（24 cases each）, control group was treated with ribavirin on the basis of conventional treatment, treatment group was treated with pegylated interferon α-2a on the basis of the treatment of the control group, and the clinical efficacy of the two groups was compared. Results Treatment group ETVR, EVR, NR, SVR and other HCV-RNA negative situation was better than the control group, the difference was statistically significant（P〈0.05）; The improvement of liver function indexes such as AST and ALT after treatment in the treatment group was significantly different between the control group and the control group, the difference was statistically significant（P〈0.05）; The incidence rate of adverse reactions in the two groups was higher than that in the treatment group, the difference between the two groups was statistically significant（P〈0.05）. Conclusion Ribavirin combined with pegylated interferon α-2a is effective and safe in the treatment of chronic hepatitis C.
出处
《中国继续医学教育》
2017年第16期151-153,共3页
China Continuing Medical Education
